Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Common antidepressants lower effects of tamoxifen in many women

20.01.2005


Additional evidence that a class of antidepressants can reduce the effectiveness of tamoxifen has been published by researchers from the Indiana University School of Medicine, the University of Michigan and Johns Hopkins University.



Results of the trial are published in the current issue of the Journal of the National Cancer Institute. The large clinical trial confirmed data from an earlier study showing that selective serotonin reuptake inhibitor antidepressants may hinder the effectiveness of tamoxifen, a drug commonly administered to breast cancer patients. The study also reports that researchers now have pinpointed genetic types that are linked with this effect.

Led by David Flockhart, M.D., Ph.D., an IU professor of medicine and director of the Division of Clinical Pharmacology, the researchers examined the effects of SSRIs in women who were prescribed tamoxifen to treat the common side effects of breast cancer therapy which include depression and hot flashes.


More than a fourth of the women enrolled in this study were prescribed SSRIs. The study showed that the various SSRIs taken by the women have different effects on the amount of active tamoxifen byproducts in their blood. "This is important because previous studies have shown that when tamoxifen is broken down, the resulting molecules are extremely powerful at blocking estrogen receptors and thereby exert a cancer-inhibitive effect," said Dr. Flockhart.

"We have withheld clinical recommendations, because at this point we don’t have final data," said Dr. Flockhart. The study makes clear that knowledge of a drug’s ability to inhibit CYP2D6 enzyme activity may help clinicians anticipate important drug interactions. Genetic testing may help identify a group of women who may experience greater benefit from tamoxifen or those who may benefit more from one SSRI than another, he said.

This study is the first large-scale clinical trial to determine the influence of multiple genetic variations and drug interactions on the plasma concentrations of tamoxifen and its active metabolites. "We can see the light at the end of the tunnel," said Dr. Flockhart. "Using our pharmacogenetic tool kit, we are very close to being able to identify which women should be given which drug to treat her depression or hot flashes."

PR Staff | EurekAlert!
Further information:
http://www.iupui.edu

More articles from Health and Medicine:

nachricht Second cause of hidden hearing loss identified
20.02.2017 | Michigan Medicine - University of Michigan

nachricht Prospect for more effective treatment of nerve pain
20.02.2017 | Universität Zürich

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Impacts of mass coral die-off on Indian Ocean reefs revealed

21.02.2017 | Earth Sciences

Novel breast tomosynthesis technique reduces screening recall rate

21.02.2017 | Medical Engineering

Use your Voice – and Smart Homes will “LISTEN”

21.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>